YOUR BRAND · YOUR CUSTOMERS · YOUR AI BUSINESS

Sell AI employees under your own brand.

Agentic AI Comparison:
Isomorphic Labs vs Kosmos

Isomorphic Labs - AI toolvsKosmos logo

Introduction

Isomorphic Labs is an AI drug-design company developing therapeutics through internal programs and pharmaceutical partnerships. Kosmos is Edison Scientific’s AI research offering for scientific literature, data analysis and research workflows. Ratings are subjective editorial opinions for each product’s stated purpose, not measured benchmarks.

Overview

Kosmos

Kosmos is Edison Scientific’s AI research offering for scientific literature, data analysis and research workflows. The current offering targets scientific R&D, particularly biopharma, combining literature, data and hypothesis work. Scientists retain experimental design, validation and interpretation responsibilities.

Isomorphic Labs

Isomorphic Labs is an AI drug-design company developing therapeutics through internal programs and pharmaceutical partnerships. Its predictive and generative models support molecular design and in-silico experiments for small molecules and biologics. Scientists must select, test and validate candidates; a designed molecule is not an approved medicine.

Editorial ratings · 1–10, higher is better

These scores express our judgement of the cited product facts. They are not measured performance benchmarks. Each product is assessed for its stated purpose; a higher score does not make different workflows interchangeable.

Evidence gaps lower confidence and affect the relevant judgement. Unknown pricing does not mean free access. Research prototypes and retired products retain their historical scope, with adoption ratings reflecting current access.

Ratings assessed: 2026-11-07. Source verification dates may differ.

Documented capability: How useful and complete is the documented workflow for the product's stated purpose?

  • 1–2: No usable current workflow established, or only an unsupported promise.
  • 3–4: Historical, experimental or very limited workflow; substantial delivery gaps.
  • 5–6: Concrete but narrow workflow, or promising research requiring specialist review.
  • 7–8: Substantial documented end-to-end workflow with useful controls or customization.
  • 9–10: Exceptionally complete documented scope and controls; reserve 10 for unusually strong evidence.

Ease of adoption: Can the intended user obtain and set up a usable product today?

  • 1–2: Discontinued, unavailable, waitlisted, or no usable deployment path verified.
  • 3–4: Archived software, restricted research/preorder access or uncertain current service access.
  • 5–6: Developer-managed setup, significant configuration or sales-led implementation.
  • 7–8: Active accessible product with manageable setup for its intended user.
  • 9–10: Straightforward self-service access and setup, with unusually few adoption obstacles.

Value and cost clarity: How attractive and understandable is the cost model for the documented use?

  • 1–2: No current purchasable or usable offer; historical prices cannot support a purchase.
  • 3–4: Material price, entitlement, license or availability uncertainty limits budgeting.
  • 5–6: Plausible value with custom pricing, significant setup costs or incomplete selected-plan terms.
  • 7–8: Useful scope with clear entry pricing/allowances or accessible source, while accounting for running costs.
  • 9–10: Exceptionally accessible and clear cost model for substantial useful scope; never assume free compute.

Integration options: How useful and extensible are the verified user-facing connections for the intended workflow?

  • 1–2: No current user-facing connection verified, or former connections are unavailable.
  • 3–4: Inputs/exports or one focused connection; internal dependencies are not native connectors.
  • 5–6: Useful API, configurable tools or several relevant connections, with limited verified breadth.
  • 7–8: Broad relevant connections or an extensible documented API/MCP/tool ecosystem.
  • 9–10: Extensive documented ecosystem with multiple connection mechanisms and strong task relevance.

Metrics Comparison

Documented capability

Isomorphic Labs: 7/10

Evidence confidence: high

Its predictive and generative models support molecular design and in-silico experiments for small molecules and biologics. Scientists must select, test and validate candidates; a designed molecule is not an approved medicine.

Kosmos: 7/10

Evidence confidence: medium

The current offering targets scientific R&D, particularly biopharma, combining literature, data and hypothesis work. Scientists retain experimental design, validation and interpretation responsibilities.

The scores judge completeness for each stated purpose; different workflows are not interchangeable.

Ease of adoption

Isomorphic Labs: 3/10

Evidence confidence: high

This is a specialist research organization and partnership route, not a self-service research assistant that an individual can subscribe to.

Kosmos: 5/10

Evidence confidence: medium

Enterprise deployment is sales-led, with implementation support and organization-specific context rather than a general free research-agent download.

Access, setup and human responsibilities matter alongside features.

Value and cost clarity

Isomorphic Labs: 3/10

Evidence confidence: high

Commercial collaborations have negotiated terms. There is no public per-seat software offer to use as a purchasing comparison.

Kosmos: 5/10

Evidence confidence: medium

Commercial terms depend on the deployment. Neither Microsoft’s unrelated Kosmos models nor open-source model licences establish this service’s price.

Compare the full cost of your intended workflow, including external services and implementation.

Integration options

Isomorphic Labs: 3/10

Evidence confidence: high

Pharmaceutical partnerships are research collaborations, not software connectors. A public general-purpose drug-design API is not part of the published offer.

Kosmos: 6/10

Evidence confidence: medium

The enterprise offer describes communication channels such as Slack, Teams and email and organization-specific deployment. Confirm the precise data/tool connections in the project scope.

Choose the connections your workflow needs, rather than counting partner logos.

Conclusions

Consider Isomorphic Labs in the context of pharmaceutical research partnerships, not as an immediately available desktop or web agent.

Consider Edison Scientific’s Kosmos for a supported scientific R&D implementation; do not confuse it with Microsoft’s similarly named models.

YOUR BRAND · YOUR CUSTOMERS · YOUR AI BUSINESS

Sell AI employees under your own brand.

Give businesses AI teams that own ongoing roles. Set your pricing, delegate routine coordination and build a recurring service.